Gavi in talks with China's Sinopharm, other vaccine makers for Covax doses

‘The GAVI Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China's state-owned Sinopharm to expand the COVAX pipeline and secure doses for distribution, a GAVI spokeswoman said on Monday.

‘Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX programme and bolstering Beijing's push for a bigger role in inoculating the world.

‘COVAX, run jointly by GAVI and the WHO to provide doses to the world's poorest people, has hit major supply problems. To date the AstraZeneca (AZN.L) shot made by the Serum Institute of India account for most doses rolled out, but authorities there have restricted exports because of India's massive epidemic.’

Read here (Reuters, May 10, 2021)

The Bill Gates factor

‘Billionaire philanthropist Bill Gates has a key role in shaping the global response to the pandemic. And it’s not good news for health equality... 

‘A charitable take is that Gavi’s work, including Covax, bridges a gap – enabling the pharmaceuticals market to serve the needs of the poorest. But its model also props up that market, simultaneously bolstering an ideology of protection for intellectual property that socializes research and development risks but privatizes profits and control.

‘Intellectual property restrictions have created monopolies in both pharmaceuticals and software, crucial for the massive profits of Microsoft, where Gates made his billions. Meanwhile the Gates Foundation also has its own investments in Big Pharma, including Pfizer, and has funded organizations lobbying for industry-friendly regulations, such as the Drug Information Association and American Legislative Exchange Council.’

Read here (New Internationalist, April 26, 2021)

Covax: A global multistakeholder group that poses political and health risks to developing countries and multilateralism

‘This report concentrates on the political and economic repercussions on the global South and how COVID and the multistakeholder structure of COVAX is driving a transformation of global governance. Multistakeholder governance is not the way to govern vaccine distribution, vaccine production, or the delivery of the vaccine to the peoples around the globe.

‘Multistakeholderism is premised on marginalising governments, inserting business interests directly into the global decision-making process, and obfuscating accountability. There are no standards of responsibility, obligation or liability for multistakeholder bodies. The multiple layers of the bodies ‘overseeing’ the multistakeholder COVAX program obscures any moral obligations, even while COVAX makes profound life decisions for hundreds of millions.

‘Probably no other commercial product has been produced that in its first years expects to have the entire world as its consumer base. COVAX as a multistakeholder body provides a gathering spot for business interests which otherwise may not be allowed to jointly plan marketing, productions, investments, and distribution in what is for them a major evolving vaccine global market. There is significant potential for commercial self-interest to be injected inappropriately into Covax decisions.’

Read here (Friends of the Earth International, Apr 7, 2021) 

How can we vaccinate the world? Five challenges facing the UN-backed COVAX programme

‘Vaccines are a key part of the solution to ending the COVID-19 pandemic and, since the early stages of the crisis, the World Health Organization (WHO) has argued that there needs to be a coordinated approach towards ensuring that everyone, not just people living in rich countries,  receives adequate protection from the virus, as it spread rapidly across the world.

‘Out of this concern grew the Global COVAX Facility, the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher and lower income countries.  

‘Here are five things to know about the challenges facing COVAX, and how they can be overcome...

1. Export controls: the weakest link?
2. Getting vaccines to those who need them is not easy
3. More funding is needed to help rollout in the poorest countries
4. Richer countries should share excess doses
5. Vaccine hesitancy: a continued cause for concern 

Read here (UN News, Apr 5, 2021) 

UN vaccine plan is underway, but problems remain

‘As the coronavirus pandemic exploded worldwide last April, global organizations banded together to help ensure that the world’s most vulnerable people would get vaccines amid the rush for shots. The initiative known as COVAX was formed by the World Health Organization, the vaccines alliance GAVI and a coalition for epidemic innovations called CEPI.

‘COVAX is supposed to make deals to buy vaccines in bulk from drug companies and can also receive donated shots from rich countries. Poorer nations can receive free doses from the initiative — and wealthier ones can also buy from it, as a way of diversifying their supply.

‘But it has been dogged by shortages of cash and supplies as well as logistical hurdles — all while a handful of rich countries raced ahead with their vaccination campaigns.’

Read here (AP, Feb 25, 2021)

Covid vaccines: G7 increase support for Covax scheme

‘G7 leaders have pledged to intensify co-operation on Covid-19 and increase their contribution to the Covax vaccine-sharing initiative. In a joint statement released after a virtual summit on Friday, G7 leaders raised their overall commitment to $7.5bn (£5.3bn). Wealthy countries are facing growing pressure to make sure lower-income nations get fair access to vaccines.’

Read here (BBC, Feb 20, 2021)

WHO vaccine scheme 'risks failure', leaving poor countries with no COVID-19 shots until 2024

 ‘In internal documents reviewed by Reuters, the scheme's promoters say the programme is struggling from a lack of funds, supply risks and complex contractual arrangements which could make it impossible to achieve its goals.

"The risk of a failure to establish a successful COVAX Facility is very high," says an internal report to the board of Gavi, an alliance of governments, drug companies, charities and international organisations that arranges global vaccination campaigns. Gavi co-leads COVAX alongside the WHO.’

Read here (Reuters, Dec 16, 2020)